Laboratory News

Saint Francis Medical Center — November 2020

GIP reagent shortage continues...

Effective on November 9, 2020, due to the lack of available reagent test kits, the Gastrointestinal Pathogen Array is no longer available for testing at either OSF HealthCare Saint Francis Medical Center Laboratory (GIP, LAB5003) or at Mayo Clinic Laboratories (GIP, LAB4809).

As soon as reagent becomes available, an updated memo will be sent out to all clients advising when testing will resume at OSF HealthCare and Mayo Clinic Laboratories. In the interim, the recommended tests that are available to be ordered at OSF are:

Test Description	OSF Orderable ID	Epic Pneumonic	CPT Code
Stool Culture	LAB1766	ST	87045, 87046
Stool, Giardia Antigen	LAB1514	GIARG	87329
Stool, Rotavirus Antigen	LAB1420	ROTAV	87425
C. difficile by PCR	LAB1829	PCRDIF	87493

For any questions regarding the reagent shortage or the available replacement testing, please contact your OSF SFMC Laboratory Clinical Representative.

Atlas Test Updates...

Effective on 10/26/2020:

1)OSF HealthCare Saint Francis Medical Center Laboratory turned on MAYO test code USTEK and turned off obsolete MAYO test code FUKAU.

2)OSF HealthCare Saint Francis Medical Center Laboratory turned on MAYO test code MPSQU and turned off obsolete MAYO test code MPSSC.

3)OSF HealthCare Saint Francis Medical Center Laboratory turned on MAYO test code WNVP.

4)OSF HealthCare Saint Francis Medical Center Laboratory turned on MAYO test code PVJAK.

5)OSF HealthCare Saint Francis Medical Center Laboratory turned on MAYO test code NSESF.

Effective on 10/29/2020:

1) OSF HealthCare Saint Francis Medical Center Laboratory turned off obsolete MAYO test code MTHFR.

2)OSF HealthCare Saint Francis Medical Center Laboratory turned off obsolete MAYO test code MTHP.

Patient COVID-19 results from SFMC...

For clients that send their COVID-19 testing (or other lab testing) to OSF HealthCare Saint Francis Medical Center Laboratory for analysis, our SFMC staff are **not** at liberty to share patient results with anyone other than the submitting location/provider.

Please **do not** have patients call the SFMC Laboratory for status updates or their results for any of their testing. If patients' would like to request results from SFMC, they must contact the SFMC Medical Records department at (309) 655-2257.

"As we express our gratitude, we must never forget that the highest appreciation is not to utter the words, but to live by them."

- John F. Kennedy

Microbiology reference workup changes...

Effective on October 14th, 2020, OSF HealthCare Saint Francis Medical Center Laboratory discontinued the below micro testing and created one micro reference workup test to streamline outpatient microbiology test ordering.

Discontinued Microbiology Tests:

Lab ID#:	Test:	Pneumonic:
LAB698	Anaerobic ID	ANERID
LAB1323	Org. ID (non-Ur.)	ORGID
LAB1437	Sens./Suscept.	SENS
LAB1665	Org. ID (urine)	UORGID

New Microbiology Test:

Lab ID#:	Test:	Pneumonic:
LAB2909	Reference Workup	SENSET

For any questions regarding these changes, please contact your OSF SFMC Laboratory Clinical Representative.

Raechel Pfahl (309) 624-9100
Sabrina Mullins (309) 624-9144

Questions??

If you are an OSF Laboratory Outreach client and you have a billing-related question, please contact OSF's Patient Accounts and Access Center billing department at (309) 683-6750.

The PAAC billing agents will be happy to assist you with your inquiry.

If you have other questions, please contact OSF's Laboratory Customer Support department at (800) 533-6730 and they will direct you to the appropriate Laboratory Mission Partner.

OSF HealthCare & Mayo Clinic present a Spotlight on Alzheimer's disease & early detection testing…

OSF HEALTHCARE SAINT FRANCIS MEDICAL CENTER SYSTEM LABORATORY & MAYO CLINIC LABORATORIES

By: Emilia Luty at Mayo Clinic Laboratories

Today, Alzheimer's is the sixth leading cause of death in the U.S.

When it comes to Alzheimer's disease, early detection is essential to better care. Through OSF HealthCare's partnership with Mayo Clinic Laboratories, OSF is able to offer an innovative evaluation for Alzheimer's disease. This evaluation uses cerebrospinal fluid (CSF) biomarkers to achieve a high concordance with an amyloid positron emission tomography (PET) scan. This new test also delivers faster results and provides new hope for correctly diagnosing and managing Alzheimer's disease along with other dementias.

Alzheimer's disease is the most common cause of dementia in older adults. It is a leading cause of disability and mortality in addition to being the most expensive disease in the United States. Over 5.8 million individuals were diagnosed with Alzheimer's disease in 2019 and an estimated 13.8 million will be diagnosed by 2050.

Definitive answers to guide better treatment…

The Alzheimer's disease CSF assay evaluates the levels of beta-amyloid 42 (Ab42), phospho-Tau (p-tau), total-Tau (t-tau), and a ratio of p-tau181 to Ab42. A reduction in CSF concentration of approximately 50% in Ab42, and an increase in p-tau and t-tau of approximately 200% are pathological hallmarks of Alzheimer's disease.

The use of biomarker testing has been included in the new consensus research diagnostic criteria for Alzheimer's disease, mild cognitive impairment (MCI), and pre-clinical Alzheimer's disease, as proposed by the National Institute on Aging and Alzheimer's Association Research Framework. Detection of amyloid deposition has been proven to change the course of treatment in 60.2% of patients with mild cognitive impairment (MCI) and 63.5% of patients with dementia.

DECREASING THE MISDIAGNOSIS OF ALZHEIMER'S PATIENTS

At Mayo Clinic Laboratories, we require a specific polypropylene low-binding tube. In clinical studies, this tube has been most effective in preventing Ab42 adsorption and can provide more accurate results for patients.

ALZHEIMER'S DISEASE EVALUATION COLLECTION KIT (T836)

Included Materials:

- 2.5-mL (75x13) low-bind Sarstedt tube with identification label
- Instructions for specimen collection
- Biohazard bag for shipment



The benefits of CSF biomarker testing…

Even though Alzheimer's disease cannot be definitively diagnosed without an autopsy, evaluating individuals for biomarkers through this new test can help differentiate Alzheimer's disease from other causes of cognitive impairment.

While Alzheimer's disease can't be cured, early diagnosis offers a variety of advantages, including medication and therapies that can be used to alleviate symptoms, and testing may allow patients to enlist in clinical trials. Ruling out Alzheimer's disease can also lead to a definitive diagnosis of other causes of dementia, some of which may be treatable.

Test Requirements…

A specific polypropylene low-binding tube is required. In clinical studies, this tube has been most effective in preventing Ab42 adsorption and can provide more accurate results for patients.

⇒ ***OSF Code:*** **ADEVL** Alzheimer Disease Evaluation, Spinal Fluid (LAB7072)

Turn-around Time…

Quicker, more affordable, and more accurate testing is key to bringing answers to at-risk populations and their caregivers. The turnaround time for the Alzheimer's evaluation is 5 to 7 days.

***These assays are being proposed as an alternative/adjunct to imaging studies to assess AD pathology. The p-Tau/Abeta42 ratio provides excellent concordance with amyloid positron emission tomography (PET) scan to assess the presence of amyloid deposition in patients with AD.*